Indaptus Therapeutics is trading 5.33% up at $1.05 despite no clearly reported company-specific announcement on August 18, 2026.
- The latest identifiable release was August 13 earnings, which described sharply reduced losses, $11.6 million in cash and short-term investments, and a strategic review following the Decoy20 trial halt.
- The Nasdaq Composite was down 1.18%; broad market sentiment does not clearly explain the move.
- Volume and a definitive catalyst were unavailable.